Pediatric Brain Tumors Market Size Forecasted To Achieve 1.82 Billion By 2029 With Steady Growth

"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Pediatric Brain Tumors Market Size and Projected Growth Rate?
The market for pediatric brain tumors has witnessed significant growth in the recent past. There is an anticipated growth from $1.4 billion in 2024 to $1.5 billion in 2025 at a Compound Annual Growth Rate (CAGR) of 7.1%. This historical growth surge is attributed to a rise in the cases of pediatric brain tumors, evolving economies, an escalation in research and development funding, as well as an increase in demand for diagnosis technology. Additionally, global occurrences of pediatric tumors have been on an upward trend.

We anticipate significant expansion in the pediatric brain tumor market in the approaching years. The market is projected to reach $1.83 billion by 2029, with a compound annual growth rate (CAGR) of 5.1%. This anticipated growth during the forecast period is due to factors like precision medicine, molecular profiling, targeted therapy, improvements in healthcare infrastructure, and broader insurance coverage. The period is also expected to witness major trends such as advancement in technologies like magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scans, the employment of genetic and molecular profiling, the creation of targeted therapies, the launch of immunotherapies, and the emergence of minimally invasive surgical procedures.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21248

What Are the Major Segments in the Pediatric Brain Tumors Market?
The pediatric brain tumors market covered in this report is segmented -

1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors
2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture
4) By Age Group: Infants, Toddlers, Children, Adolescents
5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications

Subsegments:
1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas
2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET)
3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET)
4) By Choroid Plexus Papilloma or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma
5) By Tumors Arising from Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing's Sarcoma
6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp

What Are The Driving Pediatric Brain Tumors Market Evolution?
The increase in demand for bespoke medical care is anticipated to boost the expansion of the pediatric brain tumors market in the future. Bespoke medical care is a health intervention approach that adapts treatments and medical choices to an individual's genetic composition, lifestyle, and distinctive health needs. The popularity of bespoke medical care is increasing due to advancements in genetic study, enhanced diagnostic tools, and the prospect of more efficient and precise therapies. Bespoke medicine provides targeted therapies that are more successful and inflict less harm to healthy tissue by adjusting treatments according to the specific type of a child's tumor, mutation, and response, thereby increasing outcomes and minimizing side effects. For example, as tracked by the Personalized Medicine Coalition, a US-based hospital and healthcare organization, the FDA, in 2023, granted approval to 16 new bespoke treatments for patients with rare diseases, marking a growth from only six in 2022. Consequently, the rising demand for bespoke medical care is facilitating the expansion of the pediatric brain tumors market.

Which Firms Dominate The Pediatric Brain Tumors Market Segments?
Major companies operating in the pediatric brain tumors market are AbbVie Inc., Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Ipsen Pharma, Novocure, Blueprint Medicines, Karyopharm Therapeutics Inc., Renaissance Pharma, Servier Laboratories, Matica Biotechnology, Curis Inc., Oncoheroes Biosciences, Treovir Inc., Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children's Therapeutics

What Pediatric Brain Tumors Market Trends Are Gaining Traction Across Different Segments?
Significant corporations in the pediatric brain tumors market are concentrating on creating innovative techniques such as type II RAF inhibitors to improve targeted treatments and patient results. Type II RAF inhibitors are specific therapies that aim to obstruct RAF kinases, particularly those with mutations that promote tumor expansion. These inhibitors target irregular RAF protein formations present in certain pediatric low-grade glioma (pLGG) subgroups, effectively obstructing the dysfunctional signaling routes that aid tumor cell development and survival. For example, in April 2024, Day One Biopharmaceuticals, a biotechnology company based in the United States, stated that the U.S. Food and Drug Administration (FDA) granted rapid approval for OJEMDA (tovorafenib) to be used in the recovery of relapsed or unresponsive pediatric low-grade glioma (pLGG) in patients aged 6 months and older with specific BRAF alterations. The approval of OJEMDA marks it as the first FDA-sanctioned therapy targeting BRAF fusions or mutations in this patient group. The approval relies on the reported overall response rate of 51% from the FIREFLY-1 clinical trial, which evaluated the drug's effectiveness in this indication. It is particularly meant for children with a brain tumor that have shown no reaction to previous treatments.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report

Which Is The Largest Region In The Pediatric Brain Tumors Market?
North America was the largest region in the pediatric brain tumors market in 2024. The regions covered in the pediatric brain tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Pediatric Brain Tumors Market?
2. What is the CAGR expected in the Pediatric Brain Tumors Market?
3. What Are the Key Innovations Transforming the Pediatric Brain Tumors Industry?
4. Which Region Is Leading the Pediatric Brain Tumors Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.